Corporate Partnership Program

Partner with CARRA

Advance pediatric rheumatology with the community that leads it

CARRA unites more than 800 pediatric rheumatologists, investigators, and families. Join us through an annual Corporate Partnership, Annual Scientific Meeting sponsorship, or a research project with the CARRA Registry and Biorepository.

Corporate Partner ProgramASM sponsorshipRegistry projects
A mother and daughter talk with a clinician in an exam room
Nearly 80%
of pediatric rheumatologists are CARRA members
16,000+
patients in the CARRA Registry
70
Registry sites across North America
255
research grants awarded since 2016

Why partner with CARRA

The home of pediatric rheumatology research in North America

Our mission is to unite the pediatric rheumatology community to drive research and transform the lives of children with rheumatic diseases. Corporate partnership fuels the modernization, collaboration, and field-wide infrastructure that research depends on.

Investments in the Corporate Partner Program accelerate pediatric drug development, strengthen the Registry and Biorepository for the entire community, deepen engagement with patients and families, and support the workforce needed to care for future generations.

85%+of CARRA’s expenses go directly to programs and services

What partners gain

Thought leadershipHelp shape the future of pediatric drug development through our regulatory taskforce and FDA-aligned initiative on extrapolation, trial design, and site readiness.
Clinical insightReach nearly 80% of pediatric rheumatologists through 13 scientific committees, 50 workgroups, expert meetings, and physician roundtables.
Patients and familiesBring the patient and caregiver voice into your work through focus groups and roundtables with families living with these diseases.
Workforce developmentInvest in the next generation through PREIM and a grants program that has awarded 255 grants and $12.5M+ since 2016.
Registry and BiorepositoryDraw on 16,000+ enrolled patients and 2,200+ biosamples for study-specific projects and custom data reports.

Why our partners matter to us

Our partners drive transformational change in pediatric rheumatology

Commitments made through the Corporate Partner Program advance pediatric rheumatology toward a world where every child with rheumatic disease thrives.

01

Innovation and new science

Ongoing research in immune-mediated diseases and treatment pathways to change the course of disease in children.

02

Improving standards of care

Enabling earlier, more effective interventions, helping children reach remission or low disease activity sooner, and improving quality of life.

03

Supporting a critical ecosystem

Investing in the next generation of pediatric rheumatologists, engaging with patient families, and accelerating drug development.

04

Accelerating treatment options

Thought leadership on de-risking clinical trials through alternative approaches, FDA and EMA harmonization, and partnership with the FDA.

Three ways to partner

Each opportunity stands on its own. Choose the one that fits your goals, or combine them.

Annual partnership

Corporate Partner Program

Year-round access to the experts, data, and families shaping pediatric rheumatology.

  • Input on our regulatory taskforce and our FDA-aligned initiative
  • Custom Registry and Biorepository data reports
  • Expert meetings, the Corporate Advisory Council, and patient and physician roundtables
  • Recognition in press, the annual report, and the newsletter
5partnership tiers
50workgroups
13scientific committees
Corporate Partner Prospectus
Event sponsorship

Annual Scientific Meeting

The pediatric rheumatology community’s yearly gathering, open to sponsors and exhibitors.

  • Exhibits and sponsorships
  • Industry panel sessions
  • Workgroup access
  • Engagement with patients and experts
~450attendees
11countries
38states
ASM Prospectus
Research collaboration

CARRA Registry and Biorepository

North America’s largest pediatric rheumatology registry, with more than a decade of standardized clinical data, patient-reported outcomes, and biosamples from children with JIA, SLE, JDM, and related diseases.

16,000+patients enrolled
2,200+biosamples

Biosamples include plasma, serum, cells, DNA, and RNA. Registry projects are available to Corporate Partners at every tier.

Project types

Observational studiesNatural history, disease course, and treatment patterns in children.
Post-marketing and safetyLong-term follow-up and pharmacovigilance using recorded safety events.
Comparative effectivenessHow treatments perform against each other in everyday pediatric care.
Clinical trial supportData to inform randomized and non-randomized trial design and feasibility.
Biomarker and translational researchLinked clinical data and biosamples for discovery and validation.
Custom data reportsTailored analyses of Registry data in your priority disease areas.

Thank you to our Supporter-level partners

Their support helps advance research and care for children with rheumatic diseases.

  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Cabaletta Bio
  • Johnson & Johnson
  • Sobi

Talk with our team

Let’s find the right fit for your team

Amy Beith
Corporate Partnerships Director
[email protected](404) 323-4487